Minimizing factor requirements for surgery without increased risk.
The most common type of surgical procedure in patients with haemophilia is orthopaedic surgery on the lower limb. These procedures are of great importance for the improvement of the function and quality of life of patients with haemophilia, but in many countries resources are lacking to provide the factor concentrates needed for these operations. We have attempted to reduce the level of replacement during and after total hip or total knee replacement without jeopardizing the outcome of the procedures. The results from 30 operations in 27 patients are presented. Steady-state levels down to 0.5 IU mL(-1) did not appear to increase the amount of blood loss or cause an increased incidence of complications, compared with higher levels. In addition, we review the possibilities to reduce the amount of factor concentrate by performing a combination of orthopaedic procedures and using local haemostatic agents or antifibrinolytic agents.
Schulman
S
S
Department of Hematology, Coagulation Unit, Karolinska University Hospital, S-171 76 Stockholm, Sweden. schulms@mcmaster.ca
Loogna
J
J
Wallensten
R
R
D000368:Aged; D000369:Aged, 80 and over; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D019643:Arthroplasty, Replacement / Q000379:methods*; D019644:Arthroplasty, Replacement, Hip / Q000379:methods; D019645:Arthroplasty, Replacement, Knee / Q000379:methods; D005164:Factor IX / Q000032:analysis / Q000627:therapeutic use; D005169:Factor VIII / Q000032:analysis / Q000627:therapeutic use; D006467:Hemophilia A / Q000601:surgery*; D002836:Hemophilia B / Q000601:surgery; D006470:Hemorrhage / Q000517:prevention & control; D006801:Humans; D008297:Male; D011183:Postoperative Complications / Q000209:etiology; D016896:Treatment Outcome
D000933:Antifibrinolytic Agents; D005169:Factor VIII; D005164:Factor IX